

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 5/06, 5/08		A1	(11) International Publication Number: WO 96/27658 (43) International Publication Date: 12 September 1996 (12.09.96)
(21) International Application Number: PCT/DK96/00093		(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 6 March 1996 (06.03.96)		(30) Priority Data: 0232/95 6 March 1995 (06.03.95) DK 0309/95 24 March 1995 (24.03.95) DK	
(71) Applicant (<i>for all designated States except US</i>): NOVO NORDISK A/S [DK/DK]; Novo Allé, DK-2880 Bagsvaerd (DK).		Published <i>With international search report.</i>	
(72) Inventors; and (75) Inventors/Applicants (<i>for US only</i>): GUDDAL, Erling [NO/DK]; Nykær 30, 10. th., DK-2605 Brøndby (DK). BYSKOV, Anne, Grete [DK/DK]; Solbakkevej 56, DK-2820 Gentofte (DK). GRØNVALD, Frederik, Christian [DK/DK]; Dronningeengen 19, DK-2950 Vedbæk (DK). NORDHOLM, Lars [DK/DK]; Kølegårdsvej 18A, DK-2730 Herlev (DK).		(74) Common Representative: NOVO NORDISK A/S; Corporate Patents, Novo Allé, DK-2880 Bagsvaerd (DK).	
(54) Title: STIMULATION OF MEIOSIS			
(57) Abstract <p>The present invention relates to the use of certain chemical compounds which interfere with the biosynthesis of cholesterol and medicaments comprising such compounds for stimulating the meiosis of oocytes and male germ cells <i>in vivo</i>, <i>ex vivo</i> and <i>in vitro</i>.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

STIMULATION OF MEIOSIS

FIELD OF THE INVENTION

The present invention relates to a method of inducing meiosis in a germ cell and to the use of certain chemical compounds and 5 medicaments comprising such compounds for stimulating the meiosis in vivo, ex vivo and in vitro.

BACKGROUND OF THE INVENTION

Meiosis is the unique and ultimate event of germ cells on which sexual reproduction is based. Meiosis comprises two meiotic 10 divisions. During the first division, exchange between maternal and paternal genes takes place before the pairs of chromosomes are separated into the two daughter cells. These contain only half the number ($1n$) of chromosomes and $2c$ DNA. The second meiotic division proceeds without a DNA synthesis. This 15 division therefore results in the formation of the haploid germ cells with only $1c$ DNA.

The meiotic events are similar in the male and female germ cells, but the time schedule and the differentiation processes which lead to ova and to spermatozoa differ profoundly. All 20 female germ cells enter the prophase of the first meiotic division early in life, often before birth, but all are arrested as oocytes later in the prophase (dictyate state) until ovulation after puberty. Thus, from early life the female has a stock of oocytes which is drawn upon until the stock is 25 exhausted. Meiosis in females is not completed until after fertilization, and results in only one ovum and two abortive polar bodies per germ cell. In contrast, only some of the male germ cells enter meiosis from puberty and leave a stem population of germ cells throughout life. Once initiated, 30 meiosis in the male cell proceeds without significant delay and

produces 4 spermatozoa.

Only little is known about the mechanisms which control the initiation of meiosis in the male and in the female. In the oocyte, new studies indicate that follicular purines, hypoxanthine or adenosine could be responsible for meiotic arrest (Downs, S.M. et al. Dev. Biol. 82 (1985) 454-458; Eppig, J.J. et al. Dev. Biol. 119 (1986) 313-321; and Downs, S.M. Mol. Reprod. Dev. 35 (1993) 82-94). The presence of a diffusible meiosis regulating substance was first described by Byskov et al. in a culture system of fetal mouse gonads (Byskov, A.G. et al. Dev. Biol. 52 (1976) 193-200). A meiosis activating substance (MAS) was secreted by the fetal mouse ovary in which meiosis was ongoing, and a meiosis preventing substance (MPS) was released from the morphologically differentiated testis with resting, non-meiotic germ cells. It was suggested that the relative concentrations of MAS and MPS regulated the beginning, arrest and resumption of meiosis in the male and in the female germ cells (Byskov, A.G. et al. in The Physiology of Reproduction (eds. Knobil, E. and Neill, J.D., Raven Press, New York (1994)). Clearly, if meiosis can be regulated, reproduction can be controlled. Thus, if stimulation of the meiosis of an oocyte is desired, one conceivable way of achieving this is to secure that the amount of MAS present in the environment of the oocyte outweighs the amount of MPS present. This could, in principle, be done by administering a MAS, by stimulating the secretion of a MAS or by blocking the biotransformation of a MAS already present.

SUMMARY OF THE INVENTION

It has earlier been found that administration of certain sterols known as intermediates in the biosynthesis of cholesterol leads to stimulation of the meiosis. Surprisingly, it has now turned out that administration of certain compounds,

known to interfere with the biosynthesis of cholesterol, can also lead to a stimulation of the meiosis. Although the underlying mechanism (or mechanisms) is not fully understood, it is anticipated that at least in some cases the interference 5 comprises inhibition of one or more of the enzymes involved in the bioconversion of one or more of the precursors of cholesterol. As a result of the inhibition, the concentration of the precursors formed in the steps preceding the step which has been inhibited will increase. One or more of these 10 precursors may - either directly or indirectly - cause the stimulation of the meiosis.

Accordingly, in its broadest aspect, the present invention relates to a method of stimulating the meiosis of a germ cell which comprises administering to said cell *in vivo*, *ex vivo* or 15 *in vitro* an effective amount of a compound which causes accumulation of an endogenous meiosis activating substance to a level at which meiosis is induced.

According to a preferred embodiment, the present invention relates to a method of stimulating the meiosis of a mammalian 20 germ cell.

According to another preferred embodiment, the present invention relates to a method of stimulating the meiosis of a human germ cell.

According to another preferred embodiment, the present 25 invention relates to a method of stimulating the meiosis of an oocyte.

According to another preferred embodiment, the present invention relates to a method of stimulating the meiosis of a male germ cell.

30 According to another preferred embodiment, the present

invention relates to a contraceptive method for use in females.

According to another preferred embodiment, the present invention relates to a method of treating infertility by stimulating the formation of meiotic oocytes so that an 5 increased number of meiotic oocytes are available when the ovulatory peak of gonadotropins occurs.

According to another preferred embodiment, the present invention relates to a method of treating infertility in males by stimulating the formation of spermatozoon from male germ 10 cells.

According to another preferred embodiment, the present invention relates to a method of stimulating the meiosis of a germ cell which comprises administering a compound which exhibits meiosis activating properties when tested according to 15 at least one of the methods described in the examples of the present specification.

According to another preferred embodiment, the present invention relates to a method of stimulating the meiosis of a germ cell which comprises administering amphotericin B.

20 According to another preferred embodiment, the present invention relates to a method of stimulating the meiosis of a germ cell which comprises administering aminoguanidine.

According to another preferred embodiment, the present invention relates to a method of stimulating the meiosis of a 25 germ cell which comprises administering $3\beta,5\alpha,6\beta$ -trihydroxycholestane.

According to another preferred embodiment, the present invention relates to a method of stimulating the meiosis of a germ cell which comprises administering melatonin.

According to another preferred embodiment, the present invention relates to a method of stimulating the meiosis of a germ cell which comprises administering a melatonin derivative.

According to another preferred embodiment, the present invention relates to a method of stimulating the meiosis of a germ cell which comprises administering 6-chloromelatonin.

According to another preferred embodiment, the present invention relates to a method of stimulating the meiosis of a germ cell which comprises administering 5-methoxytryptamine.

10 According to another preferred embodiment, the present invention relates to a method of stimulating the meiosis of a germ cell which comprises administering a melatonin agonist.

According to another preferred embodiment, the present invention relates to a method of stimulating the meiosis of a 15 germ cell which comprises administering any compound selected from the following list:

4 α -cyanomethyl-5 α -cholestan-3 β -ol;
4 α -nitro-5 α -cholestan-3 β -ol;
4 α -amino-5 α -cholestan-3 β -ol;
20 4 α -formyl-5 α -cholestan-3 β -ol;
4 α -aminomethyl-5 α -cholestan-3 β -ol;
4 α -(2-cyano)ethynyl-5 α -cholestan-3 β -ol;
4-allenyl-5 α -cholestan-3 β -ol;
4 α -oxirane-5 α -cholestan-3 β -ol;
25 4 α -(3,3-dichloro)vinyl-5 α -cholestan-3 β -ol;
4 α -(3,3-dibromo)vinyl-5 α -cholestan-3 β -ol;
4 α -(difluoromethyl)-5 α -cholestan-3- β -ol;
4-cyclododecyl-2,6-dimethylmorpholine;
4-tridecyl-2,6-dimethylmorpholine;
30 4-dodecyl-2,6-dimethylmorpholine;
4-[3-[4-(1,1-dimethylethyl)phenyl]-2-methylpropyl]-2,6-dimethylmorpholine;

4-[3-[4-(1,1-dimethylethyl)phenyl]-2-methylpropyl]-2,6-dimethylmorpholine-N-oxide;
cis-4-[3-[4-(1,1-dimethylpropyl)phenyl]-2-methylpropyl]-2,6-dimethylmorpholine;
5 1-[3-[4-(1,1-dimethylethyl)phenyl]-2-methylpropyl]piperidine;
8-aza-4 α ,10-dimethyl-trans-decal-3 β -ol;
N-benzyl-8-aza-4 α ,10-dimethyl-trans-decal-3 β -ol;
N-benzyl-8-aza-4 α ,10-dimethyl-trans-decal-3 β -ol-N-oxide;
N-(1,5,9-trimethyldecyl)-8-aza-4 α ,10-dimethyl-trans-decal-3 β -10 ol;
N-(1-methyldodecyl)-8-aza-4 α ,10-dimethyl-trans-decal-3 β -ol;
N-[6-(4-tert-butylphenyl)-1,5-dimethyl]hexyl-8-aza-4 α ,10-dimethyl-trans-decal-3 β -ol;
15-aza-24-methylene-D-homochosta-8,14-dien-3 β -ol;
15 4-chloro- α -[4-[2-(diethylamino)ethoxy]phenyl]- α -(4-methylphenyl)benzeneethanol;
1,4-bis(2-chlorobenzylaminomethyl)cyclohexane;
6-amino-2-penthylthiobenzothiazole;
24,25-iminolanosterol;
20 aminotriazole;
nystatin;
25-azacholesterol;
25-aza-24,25-dihydrozymosterol;
25-azacholestanol;
25 (20R)-22,25-diazacholesterol;
(20S)-22,25-diazacholesterol;
24-azacholesterol;
25-aza-24,25-dihydrolanosterol; and
23-azacholesterol.
30 According to another preferred embodiment, the present invention relates to the use of a compound which causes accumulation of an endogenous meiosis activating substance to a level at which meiosis is induced for the preparation of a medicament for inducing meiosis.

According to another preferred embodiment, the present invention relates to the use of a compound which exhibits meiosis activating properties when tested according to at least one of the methods described in the examples of the present specification for the preparation of a medicament for inducing meiosis.

According to a further preferred embodiment, the present invention relates to the use of amphotericin B for the preparation of a medicament for inducing meiosis.

10 According to a further preferred embodiment, the present invention relates to the use of aminoguanidine for the preparation of a medicament for inducing meiosis.

According to a further preferred embodiment, the present invention relates to the use of $3\beta,5\alpha,6\beta$ -trihydroxycholestane 15 for the preparation of a medicament for inducing meiosis.

According to a further preferred embodiment, the present invention relates to the use of melatonin for the preparation of a medicament for inducing meiosis.

According to a further preferred embodiment, the present 20 invention relates to the use of a melatonin derivative for the preparation of a medicament for inducing meiosis.

According to a further preferred embodiment, the present invention relates to the use of 6-chloromelatonin for the preparation of a medicament for inducing meiosis.

25 According to a further preferred embodiment, the present invention relates to the use of 5-methoxytryptamine for the preparation of a medicament for inducing meiosis.

According to a further preferred embodiment, the present

invention relates to the use of a melatonin agonist for the preparation of a medicament for inducing meiosis.

According to a further preferred embodiment, the present invention relates to the use of a compound selected from the following list for the preparation of a medicament for inducing meiosis:

- 4 α -cyanomethyl-5 α -cholestan-3 β -ol;
- 4 α -nitro-5 α -cholestan-3 β -ol;
- 4 α -amino-5 α -cholestan-3 β -ol;
- 10 4 α -formyl-5 α -cholestan-3 β -ol;
- 4 α -aminomethyl-5 α -cholestan-3 β -ol;
- 4 α -(2-cyano)ethynyl-5 α -cholestan-3 β -ol;
- 4-allenyl-5 α -cholestan-3 β -ol;
- 4 α -oxirane-5 α -cholestan-3 β -ol;
- 15 4 α -(3,3-dichloro)vinyl-5 α -cholestan-3 β -ol;
- 4 α -(3,3-dibromo)vinyl-5 α -cholestan-3 β -ol;
- 4 α -(difluoromethyl)-5 α -cholestan-3- β -ol;
- 4-cyclododecyl-2,6-dimethylmorpholine;
- 4-tridecyl-2,6-dimethylmorpholine;
- 20 4-dodecyl-2,6-dimethylmorpholine;
- 4-[3-[4-(1,1-dimethylethyl)phenyl]-2-methylpropyl]-2,6-dimethylmorpholine;
- 4-[3-[4-(1,1-dimethylethyl)phenyl]-2-methylpropyl]-2,6-dimethylmorpholine-N-oxide;
- 25 cis-4-[3-[4-(1,1-dimethylpropyl)phenyl]-2-methylpropyl]-2,6-dimethylmorpholine;
- 1-[3-[4-(1,1-dimethylethyl)phenyl]-2-methylpropyl]piperidine;
- 8-aza-4 α ,10-dimethyl-trans-decal-3 β -ol;
- N-benzyl-8-aza-4 α ,10-dimethyl-trans-decal-3 β -ol;
- 30 N-benzyl-8-aza-4 α ,10-dimethyl-trans-decal-3 β -ol-N-oxide;
- N-(1,5,9-trimethyldecyl)-8-aza-4 α ,10-dimethyl-trans-decal-3 β -ol;
- N-(1-methyldodecyl)-8-aza-4 α ,10-dimethyl-trans-decal-3 β -ol;
- 35 N-[6-(4-tert-butylphenyl)-1,5-dimethyl]hexyl-8-aza-4 α ,10-dimethyl-trans-decal-3 β -ol;

15-aza-24-methylene-D-homocholesta-8,14-dien-3 β -ol;
4-chloro- α -[4-[2-(diethylamino)ethoxy]phenyl]- α -(4-methylphenyl)benzeneethanol;
1,4-bis(2-chlorobenzylaminomethyl)cyclohexane;
5 6-amino-2-pentylthiobenzothiazole;
24,25-iminolanosterol;
aminotriazole;
nystatin;
25-azacholesterol;
10 25-aza-24,25-dihydrozymosterol;
25-azacholestanol;
(20R)-22,25-diazacholesterol;
(20S)-22,25-diazacholesterol;
24-azacholesterol;
15 25-aza-24,25-dihydrolanosterol; and
23-azacholesterol.

DETAILED DESCRIPTION OF THE INVENTION

The existence of a meiosis activating or stimulating substance has been known for some time. However, until recently, the 20 identity of the meiosis activating substance or substances was unknown.

The prospects of being able to influence the meiosis are several. According to a preferred embodiment of the present invention, the selected compounds are used to stimulate the 25 meiosis. According to another preferred embodiment of the present invention, the selected compounds are used to stimulate the meiosis in humans. Thus, the selected compounds are promising as fertility regulating agents. It can be expected that the usual side effect on the somatic cells which are known 30 from the hitherto used hormonal contraceptives which are based on estrogens and/or gestagens will not be found with the present invention. For use as a contraceptive agent in females,

meiosis can be induced so as to prematurely induce resumption of meiosis in oocytes while they are still in the growing follicle, before the ovulatory peak of gonadotropins occurs. In women, the resumption of the meiosis can, for example, be 5 induced a week after the preceding menstruation has ceased. When ovulated, the resulting overmature oocytes are most likely not to be fertilized. The normal menstrual cycle is not likely to be affected. In this connection, it is important to notice that the progesterone synthesis in cultured human granulosa 10 cells (somatic cells of the follicle) is not affected by the presence of a meiosis inducing substance, whereas the estrogens and gestagens used in the hitherto used hormonal contraceptives do have an adverse effect on the progesterone synthesis.

Stimulation of meiosis in male germ cells has also been 15 demonstrated. Accordingly, the present invention may also be useful for the treatment of infertility in males.

Lanosta-8,24-diene-3 β -ol (lanosterol) which is devoid of any meiosis activating properties is the primary cyclisation product in the sterol synthesis in mammalian cells. The 20 subsequent biosynthesis of cholesterol proceeds through a series of steps like demethylations, oxidations, reductions and displacements of double bonds, all of which are enzymatically controlled. Only some of the enzymes controlling these steps have been isolated and characterized. The first product formed 25 with a cholestane skeleton is 4,4-dimethylcholesta-8,14,24-triene-3 β -ol, which is identical with a meiosis activating compound isolated from human follicle fluid (AG Byskov et al. Nature 374 (1995) 559-562). Subsequent reduction of the double bond in the 14-position produces 4,4-dimethylcholesta-8,24-diene-3 β -ol, which is identical with a meiosis activating compound isolated from bull testes (AG Byskov et al. Nature 374 (1995) 559-562). Stepwise removal of the methyl groups in the 4-position produces 4-methylcholesta-8,24-diene-3 β -ol and cholesta-8,24-diene-3 β -ol (zymosterol) both of which have

meiosis activating properties. Subsequent migration of the double bond from the 8-position to the 5-position produces cholest-5-ene-3 β -ol (cholesterol) which has no meiosis activating properties. Inhibition of any of the enzymes which 5 are active in the series of reactions described above will cause upstream intermediates with meiosis activating properties to accumulate, thereby inducing meiosis in germ cells present.

A number of compounds known from literature have been described as inhibitors for one or more of the enzymes involved in the in 10 vivo conversion of lanosta-8,24-diene-3 β -ol to cholesterol, and the field has recently been reviewed (Mercer, E.I. Prog. Lipid Res. 32 (1993) 357-416). Amphotericin is known to interfere with the late steps of the ergosterol synthesis in fungi (Coulon, J. et al. Can. J. Microbiol. 32 (1986) 738-742) and is 15 used in the clinic as an antimycotic. In rat liver in vitro, cholestanetriol has been found to interfere with the demethylation in the 4-position of intermediates in the biosynthesis of cholesterol and thus induce accumulation of 4,4-dimethylcholesta-8-ene-3-ol and 4-methylcholesta-8-ene-3-ol 20 (Scallen, T.J. et al. J. Biol. Chem. 246 (1971) 3168-3174).

The amount to be administered of the active agent of this invention is determined according to the purpose of the treatment by those skilled in the art. The amount will depend i.a. on the specific agent in question, on the particular mode 25 of administration (e.g. in vivo, ex vivo or in vitro) and on other factors.

Compositions according to the invention for administering the active agents may be in the form of tablets, capsules, powders, solutions or suspensions. In such compositions, the active 30 agents may be combined with the carriers, adjuvants, and vehicles usually employed in the art.

A systemic effect in a living animal can be achieved by oral

administration or by injection or infusion of sterile solutions of the active agents according to the invention, the solutions being prepared according to the known art. Also, a systemic effect can be achieved by inhalation or by nasal administration 5 of a powder or an aerosol containing the active agent.

Administration of an active agent according to the invention to an isolated cell, e.g. an oocyte or a male germ cell can be achieved by keeping the cell in a medium of the kind usually employed for keeping cells of the pertinent kind in and further 10 adding the active agent to the medium.

The present invention is further illustrated by the following examples which, however, are not to be construed as limiting the scope of protection. The features disclosed in the foregoing description and in the following examples may, either 15 separately or in any combination thereof, be material for realising the invention in diverse forms thereof.

EXAMPLES

MATERIALS AND METHODS

Test of meiosis activating substances in the oocyte test.

20 Animals

Immature female mice (B6D2-F1, strain C57Bl/6J) were kept under controlled lighting (14 hr light, 10 hr dark) and temperature, with food and water ad libitum. When the animals reached a weight of 13-16 grams (which corresponds to the age of 20 to 22 25 days post partum), they were given a single injection (i.p.) of human menopausal gonadotropin (Humegon, Organon, The Netherlands) containing approximately 20 IU FSH and 20 IU LH (Ziebe, S. et al. Hum. Reprod. 8 (1993) 385-88). 48 hours later the animals were killed by cervical dislocation.

Collection and cultivation of oocytes

The ovaries were removed, placed in HX-medium (see below) and freed of extraneous tissue. The collection- and culture medium consisted of Eagles minimum essential medium (Flow, USA),
5 containing 4mM hypoxanthine (HX), 3 mg/ml of bovine serum albumin, 0.23 mM sodium pyruvate, 2 mM glutamine, 100 U/ml of penicillin, and 100 µg/ml of streptomycin (all Sigma, USA). This medium is designated HX-medium. The same medium but without HX was used as control medium.

10 The influence of the test compounds on the meiosis of oocytes was studied in cumulus enclosed oocytes (CEO, Test A) and in denuded oocytes (DO, Test B). CEO were obtained by puncturing antral follicles of the ovaries under a dissecting microscope using a 27-gauge needle. Cumulus enclosed oocyte (CEO) of
15 uniform size were selected and before use in Test A, they were rinsed three times in fresh HX-medium. Oocytes freed from cumulus cells, i.e. denuded oocytes, DO, for use in Test B were obtained by gently flushing CEO through a fine-bore mouth-controlled pipet. In Test A, CEO and in Test B, DO were
20 cultured in 4-well multidishes (Nunclon, Denmark) in 0.5 ml of HX-medium containing the test compound at the concentration stated in the tables except the controls which were cultured in control medium. Each well contained 35 to 50 oocytes. The test cultures were made with different concentrations of the
25 compounds to be tested as indicated in the tables.

The cultures were kept at 37°C and 100% humidity with 5% CO₂ in the air for 24 hours.

Priming of oocytes, Test C(A) and C(B)

Test C(A) and C(B) was carried out as Test A and Test B,
30 respectively, except that the oocytes were only kept in the medium containing the test compound for a period of time (priming period) ranging from 5 min to 3 hr at the beginning of the test. After the priming period, the oocytes were

transferred to control medium and the cultivation was continued until 22 hours after the start of the test.

Examination of oocytes

By the end of the 24 hour culture period the number of oocytes with germinal vesicle (GV) or germinal vesicle breakdown (GVBD) and those with polar body (PB) was counted in an inverted microscope with differential interference contrast equipment. The percentage of oocytes with GVBD per total number of oocytes and the percentage of oocytes with PB per GVBD were calculated. The results for the Tests A, B, C(A) and C(B), calculated as units of MAS activity, are given in the tables in each of the examples. One MAS activity unit, MASU, is defined as:

$$\frac{\% \text{GVBD}_{\text{control}}}{2}$$

The number of MAS activity units, MASU, is calculated as:

$$2 \left(\frac{\% \text{GVBD}_{\text{test}} - \% \text{GVBD}_{\text{control}}}{\% \text{GVBD}_{\text{control}}} \right)$$

EXAMPLE 1

Activation of meiosis in oocytes using cholestan-3 β ,5 α ,6 β -triol.

Test A and Test B were performed as described above, using cholestan-3 β ,5 α ,6 β -triol as test compound. The results are given in the table:

Cholestan-3 β ,5 α ,6 β -triol, μ g/ml	No. of tests	Test A, MASU	Test B, MASU
2.5	2	3.0	8.5
1.25	2	0.8	3.9
0.6	2	1.3	1.3

5 The cholestan-3 β ,5 α ,6 β -triol used was obtained from Sigma (St. Louis, USA). It appears from the table that cholestan-3 β ,5 α ,6 β -triol induces resumption of meiosis in oocytes in a dose-related manner.

10 EXAMPLE 2

Activation of meiosis in oocytes using aminoguanidine hydrogencarbonate.

15 Test A and Test B were performed as described above, using aminoguanidine hydrogencarbonate as test compound. The results are given in the table:

Aminoguanidine hydrogencarbonate, μ g/ml	No. of tests	Test A, MASU	Test B, MASU
2.5	2	3.7	2.8
1.25	2	2.5	2.4
0.6	2	2.0	0.6
0.3	2	0	0.6
0.15	2	1.2	0.8
0.08	2	2.1	1.6

20 The aminoguanidine hydrogencarbonate used was obtained from Aldrich Chemical Co., Inc. (Milwaukee, Wisconsin). It appears from the table that aminoguanidine hydrogencarbonate induces resumption of meiosis in oocytes in a dose-related manner.

EXAMPLE 3

Activation of meiosis in oocytes using amphotericin B.

Test A and Test B were performed as described above, using 5 amphotericin B as test compound. The results are given in the table:

	Amphotericin B, μg/ml	No. of tests	Test A, MASU	Test B, MASU
10	1.25	3	5.9	5.9
	0.6	2	1.3	3.7
	0.3	1	2.5	0.8

The amphotericin B used was obtained from Bristol-Myers Squibb. It appears from the table that amphotericin B induces resumption of meiosis in oocytes in a dose-related manner.

15 Amphotericin is toxic at concentrations above 1.25 μg/ml. Concentrations up to 50 μg/ml have been tested.

Priming of oocytes with amphotericin B:

The results are shown in the table:

	Amphotericin B, μg/ml	No. of tests	Priming period	Test C(A), MASU	Test C(B), MASU
20	1.25	2	5 min	0.6	0.5
	1.25	2	10 min	0.7	1.4
	1.25	2	30 min	3.7	2.1
	1.25	4	1 hr	5.0	2.7
	1.25	3	2 hr	6.4	6.1
	1.25	2	3 hr	7.6	4.4

As it appears from the table, even an exposure to amphotericin B lasting only 5 minutes is sufficient to start resumption of meiosis in both DO and CEO.

EXAMPLE 4**5 Activation of meiosis in male germ cells using amphotericin B.**

The test system consisted of foetal mouse gonads, day 11.5 p.c. One gonad from each foetus was used as control and the other one as test gonad. The gonads which differentiated during the 10 culture period were cultured for 6 days in a chemically defined culture medium under normal culture conditions, see Westergaard et al. *Fertil. Steril.* 41 (1984) 377. To the culture medium in which the test gonads were cultured varying amounts of Amphotericin B was added as indicated in the table. After the 15 culture period, the control gonads only contained non-meiotic germ cells. A semi-quantitative account of the results with the test gonads obtained by microscopy after staining is given in the table below wherein "--" indicates no response and "+", "++" and "+++" indicates increasing responses:

20

25

Amphotericin B, μg/ml	Response
10	+++
5	+++
1.25	++
0.5	+
0.1	-

The amphotericin B used was obtained from Bristol-Myers Squibb. As it appears from the table, amphotericin B activates meiosis in male germ cells in a dose-related manner.

CLAIMS

1. A method of stimulating the meiosis of a germ cell which comprises administering to said cell *in vivo*, *ex vivo* or *in vitro* an effective amount of a compound which causes accumulation of an endogenous meiosis activating substance to a level at which meiosis is induced.
2. A method according to claim 1 wherein the germ cell is a mammalian germ cell.
3. A method according to claim 1 wherein the germ cell is a human germ cell.
4. A method according to claim 1 wherein the germ cell is an oocyte.
5. A method according to claim 1 wherein the germ cell is a male germ cell.
- 15 6. A method according to claim 1 wherein the compound which causes accumulation of an endogenous meiosis activating substance is a compound which exhibits meiosis activating properties when tested according to at least one of the methods described in the examples of the present specification.
- 20 7. A method according to claim 1 wherein the compound which causes accumulation of an endogenous meiosis activating substance is selected from the group comprising amphotericin B, aminoguanidine and $3\beta,5\alpha,6\beta$ -trihydroxycholestane.
8. A method according to claim 1 wherein the compound which 25 causes accumulation of an endogenous meiosis activating substance is melatonin.
9. A method according to claim 1 wherein the compound which

causes accumulation of an endogenous meiosis activating substance is 6-chloromelatonin.

10. A method according to claim 1 wherein the compound which causes accumulation of an endogenous meiosis activating substance is 5-methoxytryptamine.

11. A method according to claim 1 wherein the compound which causes accumulation of an endogenous meiosis activating substance is a melatonin derivative.

12. A method according to claim 1 wherein the compound which causes accumulation of an endogenous meiosis activating substance is a melatonin agonist.

13. Use of a compound which causes accumulation of an endogenous meiosis activating substance to a level at which meiosis is induced for the preparation of a medicament for inducing meiosis.

14. Use according to claim 13 of a compound which exhibits meiosis activating properties when tested according to at least one of the methods described in the examples of the present specification.

20 15. Use according to claim 13 of a compound which is selected from the group comprising amphotericin B, aminoguanidine and $3\beta,5\alpha,6\beta$ -trihydroxycholestane.

16. Use according to claim 13 of melatonin.

17. Use according to claim 13 of 6-chloromelatonin.

25 18. Use according to claim 13 of 5-methoxytryptamine.

19. Use according to claim 13 of a melatonin derivative.

20. Use according to claim 13 of a melatonin agonist.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/DK 96/00093

A. CLASSIFICATION OF SUBJECT MATTER

IPC6: C12N 5/06, C12N 5/08

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC6: C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE, DK, FI, NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

MEDLINE, BIOSIS, EMBASE, CA, WPI, CLAIMS, JAPIO

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	WO 9600235 A1 (NOVO NORDISK A/S), 4 January 1996 (04.01.96) ---	1-7, 13-15
P, X	Nature, Volume 374, April 1995, Anne Grete Byskov et al, "Chemical structure of sterols that activate oocyte meiosis" page 559 - page 562 ---	1-7, 13-15

Further documents are listed in the continuation of Box C.

See patent family annex.

- * Special categories of cited documents
- "A" document defining the general state of the art which is not considered to be of particular relevance
- "B" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search

7 June 1996

Date of mailing of the international search report

13.06.96

Name and mailing address of the ISA/
Swedish Patent Office
Box 5055, S-102 42 STOCKHOLM
Facsimile No. +46 8 666 02 86

Authorized officer

Ake Lindberg
Telephone No. +46 8 782 25 00

2
INTERNATIONAL SEARCH REPORTInternational application No.
PCT/DK 96/00093

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	Dialog Information Service, File 155, Medline, Dialog accession no. 09483414, Medline accession no. 96005014, Deguchi R. et al: "Serotonin- induced meiosisreinitiation from the first prophase and from the first metaphase in oocytes of the marine bivalve <i>Hiatella flaccida</i> : respective changes in intracellular Ca ²⁺ and pH", Dev Biol (UNITED STATES) Oct 1995, 171 (2) p483-96 See abstract --	1-6,8-12, 13-14,16-20
P,X	Dialog Information Service, file 155, Medline, Dialog accession no. 09469158, Medline accession no. 95399158, Lippai M. et al: "Thimerosal triggers meiosis reinitiation in oocytes of the Japanese clam <i>Ruditapes philippinarum</i> by eliciting an intracellular Ca ²⁺ surge", Int J Dev Biol (SPAIN) Apr 1995, 39 (2) p401-7 See abstract --	1-6,8-12, 13-14,16-20
X	Dialog Information Services, file 5, Biosis, Dialog accession no. 4449558, Biosis accession no. 78023381, Skoblina M N et al: "Cholesterol Induced In-Vitro Maturation of the <i>Rana-Temporalia</i> Oocytes with and without Follicle Envelopes", ONTOGENEZ 14 (5). 1983. 484-490 See abstract --	1-7,13-15
X	Dialog Information Service, file 155, Medline, Dialog accession no. 06492824, Medline accession no. 88137824, Lanot R. et al: "Further experimental evidence for the involvement of ecdysone in the control of meiotic reinitiation in oocytes of <i>Locusta migratoria</i> ", Dev Biol (UNITED STATES) Mar 1988, 126 (1) p212-4 See abstract --	1-7,13-15

INTERNATIONAL SEARCH REPORT

International application No.
PCT/DK 96/00093

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Dialog Information Service, file 5, Biosis, Dialog accession no. 4875540, Biosis accession no. 80002851, Blondeau J-P et al: "Progesterone -Inhibited Phosphorylation of an Unique 48000- Molecular-Weight Protein in the Plasma Membrane of Xenopus-Laevis Oocytes", J Biol Chem 260 (6). 1985. 3617-3625 See abstract --	1-7,13-15
X	Dialog Information Service, file 155, Medline, Dialog accession no. 08569451, Medline accession no. 93279451, Krantic S. et al: "Evidence for a new subtype of serotonin receptor in oocytes of the surf clam <i>Spisula solidissima</i> ", Gen Comp Endocrinol (UNITED STATES) Apr 1993, 90 (1) p125-31 See abstract --	1-6,8-12, 13-14,16-20
X	Dialog Information Service, file 155, Medline, Dialog accession no. 08694925, Medline accession no. 94009925, Guerrier P. et al: "Evidence for the involvement of internal calcium stores during serotonin- induced meiosis reinitiation in oocytes of the bivalve mollusc <i>Ruditapes philippinarum</i> ", Dev Biol (UNITED STATES) Oct 1993, 159 (2) p474-84 See abstract --	1-6,8-12, 13-14,16-20
X	Dialog Information Service, file 155, Medline, Dialog accession no. 09086345, Medline accession no. 95016345, Khan NA et al: "Internalization of metformin is necessary for its action on potentiating the insulin-induced <i>Xenopus laevis</i> oocyte maturation", J Endocrinol (ENGLAND) Aug 1994, 142 (2) p245-50 See abstract --	1-5,13

INTERNATIONAL SEARCH REPORT

International application No.
PCT/DK 96/00093

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>Dialog Information Service, file 155, Medline, Dialog accession no. 04139836, Medline accession no. 80250836, Moor RM et al: "Effect of follicular steroids on the maturation and fertilization of mammalian oocytes", <i>J Embryol Exp Morphol (ENGLAND)</i> Apr 1980, 56 p319-35 See abstract</p> <p style="text-align: center;">--</p>	1-20
A	<p>The Journal of Biological Chemistry, Volume 246, No 10, May 1961, Terence J. Scallen et al, "Isolation and Characterization of C-4 Methyl Intermediates in Cholesterol Biosynthesis after Treatment of Rat Liver in Vitro with Cholestan-3Beta, 5Beta, 5Alpha, 6Beta-triol" page 3168 - page 3174</p> <p style="text-align: center;">--</p> <p style="text-align: center;">-----</p>	1-20

INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK96/00093

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: 1-12, partially because they relate to subject matter not required to be searched by this Authority, namely:
See PCT Rule 39.1. (iv): Methods for treatment of the human or animal body by surgery or therapy, as well as diagnostic methods.
2. Claims Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

01/04/96

International application No.

PCT/DK 96/00093

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A1- 9600235	04/01/96	NONE	